Actuate Therapeutics, Inc. (ACTU) — 10-Q Filings

10-Q Filings (5)

• Actuate Narrows Losses Amid R&D Cuts, Fresh Capital Influx — Nov 13, 2025 Risk: high
  Actuate Therapeutics, Inc. (ACTU) reported a net loss of $17,673,899 for the nine months ended September 30, 2025, a significant improvement from the $20,839,23
• Actuate Narrows Q2 Loss, R&D Plummets Amid Cash Burn Concerns — Aug 14, 2025 Risk: high
  Actuate Therapeutics, Inc. (ACTU) reported a net loss of $12,266,429 for the six months ended June 30, 2025, a 17.5% improvement from the $14,868,278 net loss i
• Actuate Therapeutics Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  Actuate Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending March 31, 2025. The company, formerly known as Apotheca Therapeutics, I
• Actuate Therapeutics Files Q3 2024 10-Q — Nov 13, 2024 Risk: medium
  Actuate Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business
• Actuate Therapeutics Files Q2 2024 10-Q — Sep 24, 2024 Risk: medium
  Actuate Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Apotheca Therapeutics, Inc., is in the pharmaceuti

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX